Literature DB >> 20541311

Do patients benefit from routine follow-up to detect recurrences after radical cystectomy and ileal orthotopic bladder substitution?

Gianluca Giannarini1, Thomas M Kessler, Harriet C Thoeny, Daniel P Nguyen, Claudia Meissner, Urs E Studer.   

Abstract

BACKGROUND: The need for and intensity of follow-up to detect disease recurrence after radical cystectomy (RC) for transitional cell carcinoma (TCC) remains a matter for debate.
OBJECTIVE: To determine whether diagnosis of asymptomatic recurrence after RC by routine follow-up investigations confers a survival benefit versus symptomatic recurrence. DESIGN, SETTING, AND PARTICIPANTS: Retrospective analysis of 479 patients with nonmetastatic bladder TCC receiving no neoadjuvant chemotherapy/radiation therapy and prospectively followed with a standardised protocol for a median 4.3 yr (range: 0.3-20.9) after RC at an academic tertiary referral centre. INTERVENTION: RC and extended pelvic lymph node dissection with ileal orthotopic bladder substitution. MEASUREMENTS: Cancer-specific survival (CSS) and overall survival (OS) probability for asymptomatic and symptomatic recurrent patients were estimated using the Kaplan-Meier method. The effects of age, nerve-sparing surgery, pathologic tumour stage, lymph node status, adjuvant chemotherapy, mode of recurrence diagnosis, and recurrence site on survival were assessed with multivariable Cox regression models. RESULTS AND LIMITATIONS: Of the 174 of 479 patients (36.3%) with tumour recurrence, 87 were diagnosed by routine follow-up investigations and 87 by symptoms. Routine follow-up mostly detected lung metastases and urethral recurrences, while symptoms were predominantly the result of bone metastases and concomitant pelvic/distant recurrences. Of 24 patients with urethral recurrences, 13 had carcinoma in situ (CIS). Of these, 12 were successfully managed with urethra-sparing treatment, and 6 are still alive with no evidence of disease. Most other recurrent long-term survivors had lung and extrapelvic lymph node metastases. Cumulative 5-yr survival rates of the entire cohort were 69.8% (95% confidence interval [CI], 65.5-74.3%) for CSS and 61.9% (95% CI, 57.4-66.7%) for OS. In multivariable analysis, mode of recurrence diagnosis and site of initial recurrence were the only independent predictors of CSS and OS. Patients with recurrences detected by routine follow-up investigations and with secondary urothelial tumours as site of recurrence had a slightly but significantly higher survival probability.
CONCLUSIONS: Patients diagnosed with asymptomatic recurrences during our routine follow-up after RC had a slightly higher survival than patients with symptomatic recurrences. Routine follow-up appears particularly effective in early detection of urethral CIS, which can be treated conservatively. In addition, the predominance of lung and extrapelvic lymph node metastases in survivors may justify the use of routine cross-sectional imaging. Copyright 2010 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20541311     DOI: 10.1016/j.eururo.2010.05.041

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  28 in total

Review 1.  [Treatment of bladder cancer. Value of radical prostate-sparing cystectomy].

Authors:  A Heidenreich; D Porres; D Pfister
Journal:  Urologe A       Date:  2012-06       Impact factor: 0.639

2.  A plea for a uniform surveillance schedule after radical cystectomy.

Authors:  Guido Dalbagni; Bernard H Bochner; Angel Cronin; Harry W Herr; S Machele Donat
Journal:  J Urol       Date:  2011-04-15       Impact factor: 7.450

3.  Sources of variation in follow-up expenditure after radical cystectomy.

Authors:  Goutham Vemana; Joel Vetter; Ling Chen; Gurdarshan Sandhu; Seth A Strope
Journal:  Urol Oncol       Date:  2015-04-20       Impact factor: 3.498

4.  [Peritoneal carcinomatosis after robotic-assisted radical cystectomy].

Authors:  R Epplen; D Pfister; A Heidenreich
Journal:  Urologe A       Date:  2011-11       Impact factor: 0.639

5.  SKIP expression is correlated with clinical prognosis in patients with bladder cancer.

Authors:  Longwang Wang; Mei Zhang; Yong Wu; Cheng Cheng; Yawei Huang; Zimin Shi; Hongwei Huang
Journal:  Int J Clin Exp Pathol       Date:  2014-03-15

6.  Association Between Symptomatic Versus Asymptomatic Recurrence and Survival in Bladder Cancer.

Authors:  Chelsea K Osterman; Jaber Alanzi; James D Lewis; Elizabeth L Kaufman; Vivek Narayan; Ben Boursi; Ravy K Vajravelu; Frank I Scott; S Bruce Malkowicz; Ronac Mamtani
Journal:  Clin Genitourin Cancer       Date:  2017-12-06       Impact factor: 2.872

7.  [Follow-up surveillance of muscle-invasive urinary bladder cancer after curative treatment].

Authors:  G B Schulz; C G Stief; B Schlenker
Journal:  Urologe A       Date:  2019-09       Impact factor: 0.639

8.  Recurrence patterns after open and robot-assisted radical cystectomy for bladder cancer.

Authors:  Daniel P Nguyen; Bashir Al Hussein Al Awamlh; Xian Wu; Padraic O'Malley; Igor M Inoyatov; Abimbola Ayangbesan; Bishoy M Faltas; Paul J Christos; Douglas S Scherr
Journal:  Eur Urol       Date:  2015-02-20       Impact factor: 20.096

Review 9.  Surgical resection of urological tumor metastases following medical treatment.

Authors:  Axel Heidenreich; Stefan Wilop; Michael Pinkawa; Daniel Porres; David Pfister
Journal:  Dtsch Arztebl Int       Date:  2012-09-28       Impact factor: 5.594

10.  [Follow-up care - consequences of urinary diversion after bladder cancer].

Authors:  S Degener; S Roth; M J Mathers; B Ubrig
Journal:  Urologe A       Date:  2014-02       Impact factor: 0.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.